New Myelodysplastic Syndromes Study Results Reported from Rochester General Hospital (Outcomes and Trends of Allogenic Hematopoietic Stem Cell Transplant Among MDS Patients- NIS 2016-2020).

MLA

“New Myelodysplastic Syndromes Study Results Reported from Rochester General Hospital (Outcomes and Trends of Allogenic Hematopoietic Stem Cell Transplant Among MDS Patients- NIS 2016-2020).” Medical Letter on the CDC & FDA, Dec. 2024, p. 441. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edo&AN=181763996&authtype=sso&custid=ns315887.

APA

New Myelodysplastic Syndromes Study Results Reported from Rochester General Hospital (Outcomes and Trends of Allogenic Hematopoietic Stem Cell Transplant Among MDS Patients- NIS 2016-2020). (2024). Medical Letter on the CDC & FDA, 441.

Chicago

“New Myelodysplastic Syndromes Study Results Reported from Rochester General Hospital (Outcomes and Trends of Allogenic Hematopoietic Stem Cell Transplant Among MDS Patients- NIS 2016-2020).” 2024. Medical Letter on the CDC & FDA, December, 441. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edo&AN=181763996&authtype=sso&custid=ns315887.